Cortexyme (CRTX) to Acquire Novosteo
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/5/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
Cortexyme Announces Agreement to Acquire Novosteo
May 10, 2022 8:00 AM EDTExpanding pipeline with addition of targeted therapeutics to treat rare skeletal diseases, bone cancer and injury
Strengthening leadership team with appointment of Novosteo executives Dr. Dirk Thye as CEO and Dr. Karen Smith as CMO of combined company
Planning corporate name change to Quince Therapeutics to reflect broadening of therapeutic pipeline
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company dedicated to improving the lives of patients diagnosed with degenerative diseases, today... More
